The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: A nation-wide, multicenter study

Liver International

Volumn 24, Issue 5, 2004, Pages 419-424

  Huang, Yi Hsiang ^a,b   Chen, Chien Hung ^c   Chang, Ting Tsung ^d   Chen, Shinn Cherng ^e   Wang, Shen Yung ^a   Lee, Pui Ching ^b   Lee, Hsuan Shu ^c   Lin, Pin Wen ^d   Huang, Guan Tarn ^c   Sheu, Jin Chuan ^c   Tsai, Hong Ming ^f   Chau, Gar Yang ^b   Chiang, Jen Huei ^b   Liu, Wing Yiu ^b   Lee, Shou Dong ^b   Wu, Jaw Ching ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

CLIP score; Hepatocellular carcinoma; Surgery; Transcatheter arterial chemoembolization

Indexed keywords

CISPLATIN; DOXORUBICIN; GELFOAM; IODINATED POPPYSEED OIL; MITOMYCIN C; SERUM ALBUMIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; SURVIVAL RATE; TAIWAN; CLINICAL TRIAL; INDWELLING CATHETER; LIVER TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY;

AGED; CARCINOMA, HEPATOCELLULAR; CATHETERS, INDWELLING; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TAIWAN;

EID: 16344390827     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.0941.x     Document Type: Article

References (24)

1. Department of Health, ROC. Cancer Registry Annual Report. 1998.
2. El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
3. Taylor-Robinson S D, Foster G R, Arora S, et al. Increase in primary liver cancer in UK, 1979-94. Lancet 1997; 350: 1142-3.
4. Lin D Y, Liaw Y F, Lee T Y, et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial. Gastroenterology 1988; 94: 453-6.
5. Pelletier G, Roche A, Ink O, et al. A ramdomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-4.
6. GETCH. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-61.
7. Madden M V, Krige J E, Bailey S, et al. Randomized trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993; 34: 1598-1600.
8. Bruix J, Llovet J M, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-83.
9. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998; 29: 129-34.
10. Llovet J M, Real M I, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
11. Lo C M, Ngan H, Tso W K, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
12. Kanematsu T, Matsumata T, Shirabe K, et al. A comparative study of hepatic resection and transcatheter arterial embolization for the treatment of primary hepatocellular carcinoma. Cancer 1993; 71: 2181-6.
13. Bronowicki J P, Boudjema K, Chone L, et al. Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol 1996; 24: 293-300.
14. Yoshimi F, Nagao T, Inoue S, et al. Comparison of hepatectomy and transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: necessity for prospective randomized trial. Hepatology 1992; 16: 702-6.
15. Huang Y H, Wu J C, Chau G Y, et al. Supportive treatment, resection and transcatheter arterial chemoembolization in resectable hepatocellular carcinoma: an analysis of survival in 419 patients. Eur J Gastroenterol Hepatol 1999; 11: 315-21.
16. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-5.
17. The Cancer of the Liver Italian Program (CLIP) investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31: 840-5.
18. Kaplan G L, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 453-81.
19. Cox D. Regression models and life tables. J R Stat Soc (B) 1972; 34: 187-220.
20. Llovet J M, Bruix J. Barcelona-Clinic Liver Cancer Group. Systemic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
21. Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinoma. A univariate and multivariate analysis. Cancer 1990; 65: 1104-10.
22. Poon R T P, Ngan H, Lo C M, et al. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 2000; 73: 109-14.
23. Levy I, Sherman M. The Liver Cancer Study Group of the University of Toronto. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50: 881-5.
24. Poon R T P, Fan S T, Tsang F H F, et al. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002; 235: 466-86.